Therapy News and Research

RSS

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

Human adult stem cells can regenerate damaged heart tissue: Research

Mayo Clinic investigators, with Belgian collaborators, have demonstrated that rationally "guided" human adult stem cells can effectively heal, repair and regenerate damaged heart tissue. The findings called "landmark work" in an accompanying editorial appear in today's Journal of the American College of Cardiology.

17 Aug 2010

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

An experimental drug called olaparib has been shown to shrink tumours in women whose advanced cancers were caused by faults in their BRCA genes.

17 Aug 2010

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop.The study, reported in "Cell Stem Cell" and reviewed in Cell Stem Cell and Cell, opens a new frontier for studying the molecular underpinnings of adult leukemia.

17 Aug 2010

Study finds abnormal expression of miRNAs can contribute to human diseases

Researchers at Tufts University School of Medicine and Tufts Medical Center have identified an RNA sequence that promotes increased numbers of specific microRNAs (miRNAs), molecules that regulate cell growth, development, and stress response. The discovery helps researchers understand the links between miRNA expression and disease, including heart disease and cancer. The findings are published in the August 13 issue of Molecular Cell.

17 Aug 2010

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

CEL-SCI reported a net loss for the three months ended June 30, 2010 of ($0.6) million versus a loss of ($6.2) million during the same three months in fiscal year 2009. Net loss per basic share was ($0.00) for the three months ended June 30, 2010 versus a loss per basic share of ($0.05) during the same three months in fiscal year 2009. The loss during the quarter ended June 30, 2010 was reduced by a gain on derivative instruments of $2.75 million.

17 Aug 2010

Non-viral gene therapy delays onset of eye disease

In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision. The team developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls.

17 Aug 2010

Cytomedix second quarter 2010 revenue increases 102% to $1.15 million

Cytomedix, Inc. (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced financial results for the three and six months ended June 30, 2010.

17 Aug 2010

CVS/Pharmacy opens new store in Omaha

CVS/pharmacy celebrated its entry into the Omaha market today with a grand opening at one of its two new stores in the city of Omaha. Joining CVS officials at the ceremony were The Honorable Jim Suttle, Mayor of Omaha and City Councilmember Thomas Mulligan, District #7.

16 Aug 2010

FDA grants Microsulis Medical 510(k) clearance for Acculis Accu2i percutaneous microwave tissue ablation system

Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that the U.S. Food and Drug Administration (FDA) has provided the company 510(k) clearance to market the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures.

16 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

Georgetown researcher recommends more publication on chronic sinusitis

Facial pain. Nasal congestion. Postnasal drip. Fatigue. These are hallmark signs of chronic sinusitis, a swelling of tissue in the nasal and sinus cavity. The illness strikes millions of Americans each year and is one of the top five reasons patients visit their primary care doctor. Treating sinusitis is difficult in part because it's often not known if the cause is viral or bacterial. Unfortunately little information on the subject is available to internists says a new study by a Georgetown University Medical Center (GUMC) internist.

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.

16 Aug 2010

Scientists use PCT technique to understand physical effects of compression on macromolecules

Scientists are turning to a decades-old technique to better understand the physical effects of compression on macromolecules and how it might impact their research in proteomics, mass spectrometry, protein extraction, and tissue investigations, reports Genetic Engineering & Biotechnology News.

16 Aug 2010

Johns Hopkins Professor develops ‘CAPABLE’ study to identify solutions on health challenges

In Baltimore City, dozens of older adults are now aging safely in their homes, thanks to the work of Assistant Professor Sarah L. Szanton, PhD, CRNP, at the Johns Hopkins University School of Nursing.

16 Aug 2010

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.10 per share

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months ended June 30, 2010. The Company reported a net loss of $4,623,000, or $0.10 per share, compared to a net loss of $426,000, or $0.01 per share, for the three months ended June 30, 2009. The third quarter 2010 results include a non-cash financing and change in valuation charge of $3,856,000. Loss from operations for the three months ended June 30, 2010 were $750,000 compared to $445,000 for the three months ended June 30, 2009.

16 Aug 2010

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

The easy accessibility of the eye and the established link between specific genetic defects and ocular disorders offer hope for using gene therapy to provide long-term therapeutic benefit. Two reports in the current issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc., describe the effective replacement of a human gene to preserve photoreceptor function in a mouse model of severe retinal degeneration. The articles are available free online.

16 Aug 2010

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.

16 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Therapy News and Research

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Human adult stem cells can regenerate damaged heart tissue: Research

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

Study finds abnormal expression of miRNAs can contribute to human diseases

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

Non-viral gene therapy delays onset of eye disease

Cytomedix second quarter 2010 revenue increases 102% to $1.15 million

CVS/Pharmacy opens new store in Omaha

FDA grants Microsulis Medical 510(k) clearance for Acculis Accu2i percutaneous microwave tissue ablation system

Cortex second-quarter net loss decreases to $0.04 per share

Georgetown researcher recommends more publication on chronic sinusitis

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Scientists use PCT technique to understand physical effects of compression on macromolecules

Johns Hopkins Professor develops ‘CAPABLE’ study to identify solutions on health challenges

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.10 per share

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

Inovio Pharmaceuticals 2010 second quarter net loss decreases

New T cell engineering approach can improve success rate of immune-cell therapies

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News